After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Wegovy maker Novo Nordisk is accusing Mr Huang and his firm of fraudulent claims over a hypertension drug. Read more at ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts to expand beyond its ...

Vandana Singh Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages Novo Nordisk sues KBP Biosciences ...

Pharmaceutical giant Novo Nordisk is seeking as much as US$830 million (S$1.1 billion) in damages in an application to a ...